Article Text

PDF
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: an updated meta-analysis
  1. Catherine M Olsen1,
  2. Adele C Green2,3
  1. 1Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4029, Australia
  2. 2Cancer and Population Studies Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4029, Australia
  3. 3Cancer Research UK Manchester Institute and Institute of Inflammationand Repair, University of Manchester, Manchester, United Kingdom
  1. Correspondence to Catherine M Olsen, Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4029, Australia; Catherine.Olsen{at}qimrberghofer.edu.au

Statistics from Altmetric.com

We read with interest the report by Mercer et al in the February 2017 issue of ARD1 which examined the risk of invasive melanoma in patients with rheumatoid arthritis (RA) treated with biologics. In a collaborative analysis of data from nine European countries (11 biologics registers), the authors report a pooled standardised incidence ratio (SIR) for tumour necrosis factor inhibitor (TNFi)-exposed patients of 1.2 (95% CI 0.99 to 1.6) compared with the general population (country specific) and an incidence rate ratio (IRR) of 1.1 (0.8–1.6) for TNFi-exposed patients compared with biologic naive patients. While they allowed that an increased melanoma risk in patients with RA treated with TNFi could not …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.